Status:

COMPLETED

The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream

Lead Sponsor:

Eli Lilly and Company

Conditions:

Healthy Volunteers

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

The purpose of this study is to examine the effect of gemfibrozil, ketoconazole, and clarithromycin on how much LY2409021 is found in the bloodstream and how long the body takes to get rid of it. The ...

Detailed Description

Part B was added to the trial in August 2013, per protocol amendment.

Eligibility Criteria

Inclusion

  • Participants are overtly healthy males or females, as determined by medical history and physical examination
  • Participants have a body mass index (BMI) of 18.0 to 32.0 kilograms per meter squared (kg/m\^2), inclusive, at screening
  • Participants have a fasting blood glucose of 54 to 110 milligrams per deciliter (mg/dL) (3.0 to 6.1 micromoles per liter \[mmol/L\])

Exclusion

  • Participants that have a contraindication to use of clarithromycin
  • Participants that have a personal or family history of long QT syndrome
  • Participants with a family history of sudden unexplained death or cardiac death in an immediate family member under 60 years of age
  • Participants with a personal history of unexplained syncope within the last year
  • Participants who have taken drugs or substances known to be an inducer or inhibitor of cytochrome P450 (CYP)3A4 or CYP2C8 or CYP2J2 (for example, St. John's wort, rifampin, ketoconazole, trimethoprim) within 30 days prior to the first dose

Key Trial Info

Start Date :

May 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2013

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT01836198

Start Date

May 1 2013

End Date

November 1 2013

Last Update

March 8 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Evansville, Indiana, United States, 47710